NCCN imaging appropriate use criteria published for 13 additional guidelines

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Comprehensive Cancer Network, a Centers for Medicare & Medicaid Services-approved provider-led entity for imaging appropriate use criteria continues to build its library of AUC and has published NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC) for an additional 13 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).

Launched in June 2016, NCCN Imaging AUC currently are available for 48 NCCN Guidelines. The newest NCCN Imaging AUC™ include recommendations for:

  • Anal Cancer

  • B-Cell Lymphomas

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Colon Cancer

  • Hairy Cell Leukemia

  • Hepatobiliary Cancers

  • Primary Cutaneous B-Cell Lymphomas

  • Rectal Cancer

  • Soft Tissue Sarcoma

  • Systemic Light Chain Amyloidosis

  • Testicular Cancer

  • T-Cell Lymphomas

  • Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma

NCCN Imaging AUC are an easy-to-use, single source for imaging recommendations pertaining to cancer screening, diagnosis, staging, treatment response assessment, follow-up, and surveillance as outlined within the library of NCCN Guidelines. NCCN Imaging AUC include all imaging procedures recommended in the NCCN Guidelines, including radiographs, computed tomography scans, magnetic resonance imaging, functional nuclear medicine imaging, and ultrasound.

NCCN Imaging AUC are available through a web-based user interface that provides a searchable and user-customized display of approved NCCN Imaging AUC. The complete library of NCCN Imaging AUC™ is scheduled to be available in 2017. The NCCN Guidelines are the recognized standard for clinical policy in cancer care and are often the most thorough and most frequently updated clinical practice guidelines available in any area of medicine. Other NCCN Guidelines derivative products include:

  • The NCCN Drugs & Biologics Compendium (NCCN Compendium) contains authoritative, scientifically derived information designed to support decision-making about the appropriate use of drugs and biologics in patients with cancer. The NCCN Compendium is recognized by public and private insurers alike, including CMS and UnitedHealthcare, as an authoritative reference for oncology coverage policy.

  • The NEW NCCN Radiation Therapy Compendium includes NCCN Guidelines recommendations pertaining to indications, modalities, clinical scenario, purpose, as well as the dosing regimens used for treatment. Additional information includes the clinical notes related to the specific recommendation.

  • The NCCN Biomarkers Compendium contains information designed to support decision-making around the use of biomarker testing in patients with cancer.

  • The NCCN Chemotherapy Order Templates (NCCN Templates) include chemotherapy, immunotherapy, supportive care agents, doses, schedules, monitoring parameters, and safety instructions for regimens recommended in the NCCN Guidelines.

YOU MAY BE INTERESTED IN

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has presided during his nearly four months on the job as well as even bigger cuts still looming on the horizon are a part of a single plan.
Natalie Phelps, a 43-year-old mother of two, has stage 4 colorectal cancer. She has become a central figure in the controversy over the dysfunction the Trump administration’s RIFs and budget cuts have brought to NIH. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login